Technology
Health
Biotechnology
AnaptysBio
$71.389876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$71.38
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
-$4.22 (-5.60%) Today
+$0.21 (0.30%) After Hours
Why Robinhood?
You can buy or sell AnaptysBio and other stocks, options, ETFs, and crypto commission-free!
About
AnaptysBio, Inc. Common Stock, also called AnaptysBio, is a clinical stage biotechnology company, which engages in developing antibody product candidates focused on unmet medical needs in inflammation. Read More Its pipeline includes ANB020, ANB019, and checkpoint receptor agonist antibodies. The company was founded by Andrew B. Cubitt, William J. Boyle and Nicholas B. Lydon in November 2005 and is headquartered in San Diego, CA.
CEO
Employees
78
Headquarters
San Diego, California
Founded
2005
Market Cap
1.92B
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
360.65K
High Today
$75.17
Low Today
$70.92
Open Price
$75.00
Volume
76.86K
52 Week High
$122.48
52 Week Low
$54.26
Collections
Technology
Health
Biotechnology
Medical
2017 IPO
US
North America
News
Simply Wall StMar 12
Did You Manage To Avoid AnaptysBio’s (NASDAQ:ANAB) 42% Share Price Drop?
Passive investing in an index fund is a good way to ensure your own returns roughly match the overall market. While individual stocks can be big winners, plenty more fail to generate satisfactory returns. Investors in AnaptysBio, Inc. (NASDAQ:ANAB) have tasted that bitter downside in the last year, as the share price dropped 42%. That’s well bellow the market return of 1.4%. AnaptysBio hasn’t been listed for long, so although we’re wary of recent listings that perform poorly, it may still prove itself with ...
MarketBeatMar 11
Stock Price, News, & Analysis for AnaptysBio
AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing antibody product candidates focused on unmet medical needs in inflammation. The company's proprietary anti-inflammatory pipeline includes ANB020, an anti-interleukin-33 antibody for the treatment of moderate-to-severe adult atopic dermatitis, severe adult peanut allergy, and severe adult eosinophilic asthma; ANB019, an anti-interleukin-36R antibody for the treatment of rare inflammatory diseases, including generalized pustular p...
Yahoo FinanceMar 6
All You Need to Know About AnaptysBio, Inc. (ANAB) Rating Upgrade to Buy
AnaptysBio, Inc. (ANAB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy). AnaptysBio, Inc. (ANAB) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices. A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Conse...
Price Paid on Robinhood
18% Lower
Right Now
52 Week Low
$54.26
Average Price Paid
$86.96
52 Week High
$122.48
Earnings
-$0.92
-$0.62
-$0.31
-$0.01
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
—
Actual
Expected May 7, After Hours